Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Ascites are the abnormal accumulation of fluid within the peritoneal cavity, primarily associated with cirrhosis and often marking the transition from compensated to decompensated cirrhosis. Approximately 50% of patients with decompensated cirrhosis develop ascites within 10 years, leading to increased mortality due to complications like spontaneous bacterial peritonitis and hepatorenal syndrome. In the United States, cirrhosis is the leading cause of ascites, accounting for about 80% of cases. Other causes include cancer (10%), heart failure (3%), tuberculosis (2%), dialysis (1%), pancreatic disease (1%), and other factors (2%). Hemorrhagic ascites, occurring in up to 19% of cirrhosis patients, may result from spontaneous causes, with 72% attributed to bloody lymph and 13% to hepatocellular carcinoma. The initial abnormality in cirrhosis-related ascites is portal hypertension, where increased portal pressure and elevated circulating nitric oxide levels lead to vasodilation. As vasodilation progresses, plasma levels of vasoconstrictor sodium-retentive hormones rise, renal function declines, and ascitic fluid accumulates, indicating hepatic decompensation. The treatment of ascites depends on the underlying cause of fluid retention. Goals include minimizing ascitic fluid volume and reducing peripheral edema without inducing intravascular volume depletion. Sodium restriction and diuretics are fundamental to treatment. For high-albumin-gradient ascites seen in cirrhosis, treatment involves:
• Alcohol abstinence
• Limiting dietary sodium to 88 mEq (2000 mg) per day
• Administering diuretics (spironolactone and furosemide in a 100:40 mg/day ratio)
Spontaneous bacterial peritonitis, an infection of ascitic fluid with no apparent cause, is a common complication in people with ascites and cirrhosis, especially those with heavy alcohol consumption. Symptoms may include abdominal discomfort, tenderness, fever, confusion, and drowsiness. Prompt treatment with appropriate antibiotics is crucial for survival, as untreated cases can be fatal.

Thelansis’s “Ascites Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ascites treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Ascites across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ascites Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Ascites – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033